Range of suitable people: CDEC talked over the uncertainty in the number of patients with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers that are labeled as obtaining delicate or moderate illness may have a serious bleeding phenotyp